Active substance
Results for the substance ceritinib
1 result
About this active substance
Ceritinib is a kinase inhibitor used for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with an ALK (anaplastic lymphoma kinase) mutation. It works by blocking the activity of the ALK kinase, thereby inhibiting the growth and spread of cancer cells.
The medication is taken orally, usually once daily, and the dosage is adjusted based on the patient's response and tolerance to the treatment. Ceritinib is primarily used in patients who do not respond to other therapies or who have progressed after previous treatments.
Patients should be closely monitored to detect potential side effects, such as nausea, diarrhea, abdominal pain, or elevated liver enzymes. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include nausea, diarrhea, fatigue, vomiting, and weight loss. In rare cases, severe reactions such as pneumonitis or hepatotoxicity may occur. Patients should be informed of these risks before starting treatment.
The medication is taken orally, usually once daily, and the dosage is adjusted based on the patient's response and tolerance to the treatment. Ceritinib is primarily used in patients who do not respond to other therapies or who have progressed after previous treatments.
Patients should be closely monitored to detect potential side effects, such as nausea, diarrhea, abdominal pain, or elevated liver enzymes. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include nausea, diarrhea, fatigue, vomiting, and weight loss. In rare cases, severe reactions such as pneumonitis or hepatotoxicity may occur. Patients should be informed of these risks before starting treatment.